home All News open_in_new Full Article

IDE034, a Bispecific ADC Licensed by Biocytogen to IDEAYA, Receives FDA IND Clearance

BEIJING — Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), announced that its partner IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision oncology company, has received the clearance of an investigational new drug (IND) application with the U.S. Food and Drug Administration (FDA) for the initiation of a Phase 1 clinical trial of IDE034, a potential […]


today 23 h. ago attach_file Other

attach_file Other
attach_file Economics
attach_file Other
attach_file Other
attach_file Culture
attach_file Economics
attach_file Other
attach_file Society
attach_file Other
attach_file Sport
attach_file Events
attach_file Other
attach_file Other
attach_file Sport
attach_file Economics
attach_file Other
attach_file Other
attach_file Other
attach_file Society
attach_file Culture


ID: 3236077810
Add Watch Country

arrow_drop_down